An Update on Self-Amplifying mRNA Vaccine Development


Authors: A.K. Blakney, S. Ip. and A.J. Geall

Journal: Vaccines

DOI: 10.3390/vaccines9020097

Publication - Abstract

January 28, 2021

Vaccines Nucleic Acid Lipid Nanoparticles mRNA

Abstract

This review will explore the four major pillars required for design and development of an saRNA vaccine: Antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)). We report on the major innovations, preclinical and clinical data reported in the last five years and will discuss future prospects.
 

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Sep 29, 2020
Nature Communications

Development of an ObLiGaRe Doxycycline Inducible Cas9 System for Pre-clinical Cancer Drug Discovery

A. Lundin, M.J. Porritt, H. Jaiswal, F. Seeliger, C. Johansson, M. Maresca et. al.

mRNA Oncology Nucleic Acid Lipid Nanoparticles
Read More


Publication - Abstract

Sep 09, 2021
Signal Transduction and Targeted Therapy

The Self-Assembled Nanoparticle-Based Trimeric RBD mRNA Vaccine Elicits Robust and Durable Protective Immunity Against SARS-CoV-2 in Mice

W. Sun, L. He, H. Zhang, X. Tian, Z. Bai, L. Sun, L. Yang, X. Jia, Y. Bi, T. Luo, G. Cheng, W. Fan, W. Liu & J. Li

Nucleic Acid Lipid Nanoparticles mRNA
In a publication written by scientists, Sun et al. 2021, from the CAS Key Laboratory of Pathogenic Microbiology and Immunology at the Chinese Academy of Sciences, endeavored to develop a broad-spectrum multivalent vaccine to combat rapidly emerging variants of SARS-CoV-2. Their a...
Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Cytiva, formerly Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up